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Breast cancer stem cells (BCSCs) are the minor population of breast cancer (BC)
cells that exhibit several phenotypes such as migration, invasion, self-renewal, and
chemotherapy as well as radiotherapy resistance. Recently, BCSCs have been more
considerable due to their capacity for recurrence of tumors after treatment. Recognition
of signaling pathways and molecular mechanisms involved in stemness phenotypes of
BCSCs could be effective for discovering novel treatment strategies to target BCSCs.
This review introduces BCSC markers, their roles in stemness phenotypes, and the
dysregulated signaling pathways involved in BCSCs such as mitogen-activated protein
(MAP) kinase, PI3K/Akt/nuclear factor kappa B (NFκB), TGF-β, hedgehog (Hh), Notch,
Wnt/β-catenin, and Hippo pathway. In addition, this review presents recently discovered
molecular mechanisms implicated in chemotherapy and radiotherapy resistance,
migration, metastasis, and angiogenesis of BCSCs. Finally, we reviewed the role of
microRNAs (miRNAs) in BCSCs as well as several other therapeutic strategies such
as herbal medicine, biological agents, anti-inflammatory drugs, monoclonal antibodies,
nanoparticles, and microRNAs, which have been more considerable in the last decades.
Keywords: angiogenesis, breast cancer stem cell, chemotherapy and radiotherapy resistance, invasion,
metastasis
INTRODUCTION
The most common cancer among women all over the world is breast cancer (BC). The prevalence
of BC is increasing; according to the recent report (2020), 279,100 new cases and 42,690 deaths of
BC have been estimated in the United States (https://doi.org/10.3322/caac.21590). Approximately
25% of cancers in women and 15% of cancer deaths are caused by BC. About 0.8–1% of all BCs
are due to male breast carcinoma, although the incidence of BC in men has increased recently. It
has been estimated that the prevalence of BC in the world will reach 2.3 million by 2030 (1, 2). The
most important factors for promoting BC are high expression level of estrogen, estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). On the
other hand, mutation in tumor suppressor genes such as BRCA1 and BRCA2 is the most important
reason for familial BC (3). There are two types (ductal and lobular) and multiple subtypes [luminal
A and B, basal-like triple negative breast cancer (TNBC), HER2+, and claudin-low] of BC that are
classified by molecular and histological phenotypes. Each type and subtype of BC are categorized to
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non-invasive and invasive (2, 4–7). A population of cancer cells
in BC tissues makes the treatment of BC obscure. Cancer stem
cells (CSCs) are a type of BC cells with some stemness phenotypes
such as self-renewal, differentiation, metastasis, migration, and
therapeutic resistance that make tumors more progressive and
aggressive (8–10). Breast tumor consists of 2% breast cancer stem
cells (BCSCs), in which their resistance to chemotherapy and
radiotherapy can cause treatment failure and disease recurrence
(8). There is a controversy among researchers about the origin
of BCSCs, in which normal stem cells, progenitor cells, or
differentiated cells can be considered as an origin of BCSCs (11).
Deregulation of signaling pathways including mitogen-activated
protein (MAP) kinase, PI3K/Akt/nuclear factor kappa B (NFκB),
TGF-β, hedgehog (Hh), Notch, Wnt/β-catenin, and Hippo
pathway in normal stem cells, progenitor cells, or differentiated
cells may transform them to CSCs due to genetic and epigenetic
changes (12–14). In addition, the expression of the specific
molecules in these signaling pathways can be deregulated in
BCSCs as well as microRNAs (miRNAs). It has been reported that
there are several miRNAs that have been upregulated in BCSCs
(Table 1). Downregulation of these miRNAs has been suggested
as a novel treatment strategy of BC (Table 2). Alternative
strategies are being used to target BCSCs directly. In this
review, we have summarized the malignant characterization of
BCSCs such as drug and radiotherapy resistance, metastasis and
Abbreviations: ADAM17, ADAM metallopeptidase domain 17; ALDH, aldehyde
dehydrogenase; ASA, aspirin; ATM, ataxia telangiectasia mutated; ATR, ATM-
and RAD3-related; DAC, 5-aza-2′-deoxycytidine; β-TrCP, beta-transducin repeat-
containing proteins; BC, breast cancer; BCSCs, breast cancer stem cells; CSCs,
cancer stem cells; COMP, cartilage oligomeric matrix protein; CAT, catalase;
COX, cyclooxygenase; DLL, delta like protein; DUBs, deubiquitinating enzymes;
DUSP9/DUSP16, dual specificity phosphatase; EpICD, EpCAM intracellular
domain; EGFR, epidermal growth factor receptor; EMT, epithelial–mesenchymal
transition; ESA, epithelial specific antigen; ER, estrogen receptor; ECM1,
extracellular matrix protein 1; FAM3C, family with sequence similarity 3 member
C; FMSP, 1-ferrocenyl-3-(4-methylsulfonylphenyl)propen-1-one; PDE3A,
phosphodiesterase 3A; FGF1, fibroblast growth factor 1; FKBPL, FK506-binding
protein like; FAK, focal adhesion kinase; FHL2, four and a half LIM domains
2; GPx, glutathione peroxidase; GSK3β, glycogen synthase kinase 3 beta; Hh,
hedgehog; HDL, high-density lipoproteins; Hmga2, high mobility group AT-
Hook 2; HMGB1, high-mobility-group box 1; HER2, human epidermal growth
factor receptor 2; Has2, hyaluronan synthase 2; HAS2-AS, hyaluronan synthase
2-antisense; HA, hyaluronic acid; HMGCS2, 3-hydroxy-3-methylglutaryl-
CoA synthase 2; HIF1, hypoxia-inducible factor-1; IKKα, IκB kinase α; IAPs,
inhibitors of apoptosis proteins; IL-6, interleukin-6; ILEI, interleukin-like
EMT inducer; CD44-ICD, intracellular domain fragment of CD44; KIF11,
kinesin family member 11; LncRNA, long non-coding RNA; LDL, low-density
lipoproteins; MNK, MAPK interacting kinase; MMP, matrix metalloprotease;
MT1-MMP, membrane type 1-matrix metalloprotease; MitoVES, Mito Vitamin
E succinate; MUC1, mucin1; MDR, multidrug resistance; NRPs, neuropilins;
NADP, nicotinamide adenine dinucleotide phosphate; NICD, notch intracellular
membrane domain; OPN, osteopontin; PATJ, Pals1-associated tight junction;
PG, phloroglucinol; PSEN2, presenilin-2; PR, progesterone receptor; PDCD4,
program cell death protein 4; PD-1, programmed death 1; PKCε , protein kinase
Cε ; PRKD1, protein kinase D1; Pso, psoralidin; Rac GAP, Rac GTPase-activating
protein; RANKL, RANK ligand; ROS, reactive oxygen species; RANK, receptor
activator of NFκB; RTK, receptor tyrosine kinase; ROK, rho kinase; SHH, Sonic
hedgehog; SOD, superoxide dismutase; Tbx3, T-box transcription factor 3; TSP-1,
thrombospondin-1; TLRs, Toll-like receptors; TGF-β, Transforming growth
factor beta; TG2, transglutaminase; TNBC, triple negative breast cancer; USP,
ubiquitin specific peptidase; VEGF, vascular endothelial growth factor; VLDL,
very-low-density lipoproteins; ZEB1, zinc finger E-box binding homeobox 1.
TABLE 1 | MicroRNAs (miRNAs) upregulated in breast cancer stem cells (BCSCs).
miRNA Target Result References
miR-10b Hox D10 -Metastasis (15)
miR-21 PTEN -Activates Akt/ERK1/2
pathways
-EMT
-Invasion
-Metastasis
(16, 17)
miR-22 Hypermethylation of
miR-200 promoter,
miR-200 inactivation,
ZEB1/2, and BMI1
expression
-EMT
-Metastasis
(18)
miR-125 Bak1 Promotes CSC
maintenance
(19)
miR-181 BRCA1 Promotes CSCs
phenotypes
(20)
miR-221/222 PTEN -Activate PI3K/Akt
pathway
-xIncrease proliferation
(21)
Akt phosphorylation
Hox D10, Homebox protein D10; PTEN, phosphatase and tensin homolog; EMT,
epithelial–mesenchymal transition; ZEB1/2, zinc finger E-box binding homeobox 1/2;
BMI1, B lymphoma Mo-MLV insertion region 1; homolog, a member of the polycomb
repression complex 1 family; Bak1, BCL2 antagonist/killer 1; BRCA1, breast cancer type
1 susceptibility protein.
angiogenesis, biomarkers, and mechanisms involved in drug and
radiotherapy resistance. We have assessed signaling pathways
that are responsible for maintaining stemness phenotypes
as well as miRNAs in BCSC. The recognition of signaling
pathways and molecular mechanisms involved in stemness
phenotypes of BCSCs would be effective for discovering novel
treatment strategies to target BCSCs. Finally, we have reviewed
several therapeutic strategies that have been investigated in the
last decades.
BCSC MARKERS
BCSCs express variety of specific markers such as
CD44+/CD24−, CD326 (EpCAM), epithelial specific antigen
(ESA), and aldehyde dehydrogenase (ALDH) activity in different
types of BC. Unlike CD24, known as a differentiated BC cells
marker, CD44 has been identified as a stemness marker on the
surface of BCSCs. CD44 is bonded to hyaluronic acid (HA)
and extracellular matrix proteins such as osteopontin (OPN)
and matrix metalloprotease (MMP) (44). CD44 with receptor
tyrosine kinase (RTK) may control cell adhesion, migration,
and transmission of proliferation signals in BCSCs (45). Several
signaling pathways such as Rho GTPases, Ras-MAPK, and
PI3K/Akt involved in the regulation of cell adhesion, migration,
invasion, and epithelial–mesenchymal transition (EMT) are
mediated by CD44 (46). However, CD44+ cannot be very helpful
as a definite marker for isolation and detection of BCSCs in
all types of BC (5, 47, 48). Luminal and basal/mesenchymal
BCs have CD44−/CD24+ and CD44+/CD24− phenotypes,
respectively, whereas basal/epithelial BC is positive for both
markers (49). Frequency of BCSCs with CD44+/CD24− is
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TABLE 2 | MicroRNAs (miRNAs) targeting breast cancer stem cells (BCSCs).
miRNA Target Result on BCSCs References
miR-7 KLF4 -Reduces stemness phenotypes
-Inhibits pluripotent potential of stem cells
(22)
miR-9 Notch signaling Reduces metastasis (23)
miR-16 WIP1 -Reduces self-renewal
-Increases sensitivity to doxorubicin (Dox)
(24)
miR-23b MARCKS -Inhibiting cell cycle
-Inhibiting motility
(25)
miR-29b -SPIN1
-Wnt/β-catenin and Akt signal pathways
-VEGFA
-PDGFA/B/C
-MMP2/9, ITGA6,
-ITGB1, TGFβ2/3
-Inhibits self-renewal and growth
-Inhibits invasion and metastasis
(26)
miR-30a Protein AVEN -Inhibits the growth
-Induces apoptosis
(27)
miR-30e -Ubc9 -ITGB3 -Inhibits self-renewal
-Induces apoptosis
(28)
miR-34 family (miR-34a
and miR-34c)
-Notch signaling
-Notch4
-Reduces cancer stem cell phenotypes
-Suppresses EMT
-Suppresses metastasis
-Increases sensitivity to Dox and paclitaxel
(23, 29, 30)
miR-93 Sox4 -Reduces stemness phenotypes
-Promotes differentiation
-Inhibits pluripotent potential of stem cells
(31)
miR-126/miR-
206/miR-335
-Sox4
-Tenascin C
-Reduces stemness phenotypes and proliferation
-Inhibits metastasis and migration
(32)
miR-128 -Nanog
-Snail
-Reduces stemness phenotypes
-Inhibits pluripotent potential of stem cells
(33, 34)
miR-140 -Sox9
-ALDH1
-Reduces stemness phenotypes
-Inhibits pluripotent potential of stem cells
(35)
miR-148 -BMI1
-ABCC5
-Inhibits progression
-Induces apoptosis
-Increases sensitivity to Dox
(33, 34)
miR-153 HIF1α Inhibits angiogenesis (36)
miR-200 family
(miR-200a, miR-200b,
and miR-200c)
-BMI1
-Suz12
-Notch pathway components,
Jagged1, Maml2/3
-ZEB1/2
-Suppresses colony formation
-Suppresses tumor formation
-Suppresses invasion
-Suppresses EMT
(37–39)
miR-600 -SCD1 enzyme
-Wnt/β-catenin pathways
Promotes differentiation (40)
miR-708 Neuronatin
ERK/FAK pathway
Inhibits migration and metastasis (41)
let-7 -H-RAS
-MYC
-HMGA2
-IL-6
-ERα
-Inhibits self-renewal
-Inhibits pluripotent potential of stem cells
(42, 43)
KLF4, Kruppel-like factor 4; WIP1, wild-type p53-induced phosphatase 1; MARCKS, myristoylated alanine rich protein kinase C substrate; SPIN1, Spindlin 1; VEGFA, vascular endothelial
growth factor A; PDGFA/B/C, platelet-derived growth factor A/B/C; MMP2/9, matrix metalloproteinases 2/9; ITGA6, integrin subunit alpha 6; ITGB1, integrin subunit beta 1; TGFβ2/3,
transforming growth factor beta 2/3; Protein AVEN, apoptosis and caspase activation inhibitor; Ubc9, hypothetical protein; ITGB3, integrin subunit beta 3; EMT, epithelial–mesenchymal
transition; ALDH1, aldehyde dehydrogenase 1; BMI1, B lymphoma Mo-MLV insertion region 1 homolog, a member of the polycomb repression complex 1 family; ABCC5, multidrug
resistance-associated protein 5; HIF1α, hypoxia-inducible factor 1α; Suz12, polycomb repressive complex 2 subunit; Maml2/3, mastermind-like Notch coactivators 2/3; ZEB1/2, zinc
finger E-box binding homeobox 1; SCD1, stearoyl-CoA desaturase-1; HMGA2, high-mobility group AT-hook 2; IL-6, interleukin 6; ERα, estrogen receptor α.
significantly more in TNBCs (44). In addition, PR and ER
messenger RNA (mRNA) levels in cells with the markers of
CD44+/CD24−/ALDH+ significantly are less in comparison
with cells with phenotype of CD44−/CD24+ (11). ALDH
activity is a better predictive marker in parallel with higher
tumorigenic activity in vivo in comparison with CD44/CD24
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markers (50, 51). ALDH enzyme is responsible for intracellular
aldehyde oxidation and has a critical role in differentiation of
stem cells (52). To detect ALDH activity using Aldeflour assay
kit, ALDH converts BODIPY-aminoacetaldehyde substrate to
BODIPY-aminoacetate, a fluorescent product detectable by flow
cytometry (51). The other important marker is ESA or CD326.
ESA is a protein marker that is expressed on the surface of BCSCs
essential for cell adhesion, proliferation, migration, and invasion
of BC cells through Wnt signaling pathway (53). A regulated
intramembrane proteolysis by ADAM metallopeptidase domain
17 (ADAM17) and Presenilin-2 (PSEN2) involves breakage of
EpCAM intracellular domain(EpICD). EpICD binds to a half
LIM domains 2 (FHL2) and β-catenin and forms a nuclear
protein complex, which expresses genes involved in stemness
physiological features (54). The other markers mostly used
for isolation and identification of BCSCs in all types of BCs
are CD133, CD166, Lgr5, CD47, and ABCG2 (55). A recent
study indicated that transglutaminase (TG2) is expressed highly
in CSCs and is involved in the expression of CSC markers,
proliferation, drug resistance, migration, invasion, and EMT of
CSCs. This protein is dependent to Ca2+ and GTP localized in
cytosol, nucleus, cell membrane, and extracellular environment
and can be converted to both open (Ca2+-bonded cross-linking
form) and closed (GTP-bonded signaling form) configurations.
Closed configuration has a vital role in BC progression and CSC
survival through activation of NFκβ, Akt, and focal adhesion
kinase (FAK) signaling (56).
It has been reported that the use of radiation to destroy
cancer cells after surgery may convert differentiated cancer
cells to CSCs through the expression of CSC markers such as
Oct4/Sox2/KLF4. Therefore, in some cancer cases, radiation is
not recommended, as it can involve recurrence and metastasis
(57). Hypoxia, generated in the depths of the tumor due to
lack of oxygen and blood vessels, may regulate the expression
of genes involved in CSCs. It may increase the number of
CSCs through the conversion of differentiated cancer cells to
CSCs (4).
SIGNALING PATHWAYS REGULATE BCSCs
It has been noted that a number of signaling pathways
including MAP kinase, PI3K/Akt/NFκB, TGF-β, hedgehog
(Hh), Notch, Wnt/β-catenin, and Hippo signaling have been
implicated in stemness maintenance and regulation of self-
renewal, metastasis, and therapeutic resistance into CSCs (12,
14, 56–61). Deregulation of these pathways in normal stem
cells may transform them to CSCs. CSCs markers could show
a vital role in the regulation of signaling pathways. There is
a relationship between CD24 and Sonic hedgehog (SHH), as
knocking down CD24 in breast cancer cells have demonstrated
increased proliferation, invasion, and tumorigenicity through
higher expression of SHH, GLI1, and MMP2. CD24 suppresses
the malignant phenotype of BCSCs by downregulating SHH
expression through STAT1 inhibition (12) (Figure 1). However,
cells with high expression of CD44 show higher expression
level of β-catenin and Notch1 and Ki67 (62). CD44-PKC-Nanog
signaling axis is involved in BCSCs. Binding of CD44 with
protein kinase Cε (PKCε) is mediated by hyaluronan and
regulates human breast tumor cells and BCSC functions.
Activated PKCε increases phosphorylation of Nanog, a stem
cell marker. Phosphorylated Nanog is translocated into the
nucleus and increases miR-21 expression and decreases tumor
suppressor program cell death protein 4 (PDCD4) expression.
Along with this process, inhibitors of apoptotic proteins (IAPs)
and MD11 are upregulated and then leads to antiapoptosis
and chemotherapy resistance in BCSCs (63). The other
pathway that is mediated by CD44–hyaluronan is HA/CD44-
induced c-Jun signaling. Activated c-Jun is translocated into
the nucleus and stimulates miR-21 expression, antiapoptosis
protein Bcl-2, and IAPs (64). In addition, HA–CD44 interaction
promotes c-Src kinase activation and Twist phosphorylation.
Phosphorylated Twist is translocated into the nucleus and
activates miR-10a expression through binding to Twist binding
site(s). This process leads to a decrease in tumor suppressor
HOXD10, upregulation of RhoA/RhoC, and stimulation of
RhoGTPase-Rho kinase (ROK). ROK activation leads to
cytoskeleton activation and breast cancer cell invasion (65)
(Figure 1).
In addition, EMT is a process that converts cells with
epithelial to mesenchymal phenotypes through decrease in cell–
cell adhesion and increase in cell metastasis (40). There are
many mediators such as growth factors (epidermal growth
factor and TGF-β) that have been involved in several signaling
pathways including TGF-β, PI3K/Akt, Wnt, and MAPK and
regulate EMT (66). Induction of EMT in normal and cancer
cells can generate CSCs with high expression of respective
markers, mammosphere formation, colony formation, as well
as invasion and metastasis (67). One of the most important
levels in the regulation of EMT is the regulation of EMT-
inducing transcription factors such as ZEB, Snail, Slug, and Twist.
These transcription factors induce EMT through activation of
the specific molecular programs in different signaling pathways,
which mediate repression of epithelial markers including E-
cadherin and induce mesenchymal markers such as vimentin
(68, 69). It has been reported that high expression level of
ZEB1 has been associated with the activity of several specific
molecules, FOXC2, NFκB, SOX2, BCL6, and HIF1α involved in
EMT and malignancy of BCSCs (68). Overall, EMT transcription
factors contributed to the regulation of signaling pathways in
CSCs (66).
MAPK Signaling Pathway
Several studies have shownMAPK signaling activity in aggressive
BC and BCSCs. One of the pathways activatesMAPK signaling in
BCSCs, which is mediated by epidermal growth factor receptor
(EGFR) and HER2. In this way, activated ERK stimulates MAPK
interacting kinase (MNK) signaling, and then, MNK activates
XIAP, its downstream protein. XIAP is an apoptotic inhibitor
protein that is upregulated in inflammatory and aggressive BC
and links NFκβ signaling activity toMAPK signaling (14). On the
other hand, IAP upregulates Snai2 expression, an EMT factor that
has an association with increased stem cell properties. Inhibition
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FIGURE 1 | Role of CD24 and CD44 in inhibition and promotion of BCSCs, respectively. CD24 inhibits stemness phenotypes of BCSCs through inhibition of STAT1
and SHH. However, CD44 promotes chemotherapy resistance and invasion of BCSCs through CD44–PKCε-Nanog signaling axis and inducing c-Jun signaling.
of IAP protein decreases MAPK activity through downregulation
of EGFR and Snai2 expression (70) (Figure 2).
One of the other MAPK activating signaling pathways in
BCSC resistance to chemotherapy is mediated by hypoxia-
inducible factor-1 (HIF1)-dependent manner. Chemotherapy in
an HIF1-dependent manner regulates the expression of dual
specificity phosphatase (DUSP9) and DUSP16. Reciprocally,
increased expression of DUSP9 inhibits ERK and decreased
expression of DUSP16, which activates p38 signaling pathway.
ERK inhibition leads to increased expression of Nanog through
decreased phosphorylation of FoxO3, and p38 activation
stabilizes transcripts of stemness genes such as Nanog and KIF4
via ZFP36L1 phosphorylation, which has been known as aNanog
and KIF4mRNA binding protein (71) (Figure 2).
p38δ MAPK is involved in cancer cell progression, metastasis,
and regulation of BCSC phenotypes as well as EMT. p38δMAPK-
mediated EMT is promoted by the inhibition of miR200b, the
downstream of p38γ MAPK. p38γ MAPK inhibits miR200b
through induction of GATA3 ubiquitylation and its degradation.
Then, expression of a polycomb group protein, Suz12, which is a
target of miR200b, promotes EMT (72) (Figure 2).
PI3K/Akt/NFκB Signaling Pathway
It has been reported that the PI3K/Akt/NFκB axis has
been involved in the characterization and drug resistance of
BCSCs. Suppressed PI3K/Akt in CSCs overcomes the multidrug
resistance (MDR) phenotype through induction of cell apoptosis.
The role of PI3K/Akt in BCSCsmay bemediated by HER2, which
makes tumors more aggressive through unknown mechanism
(58). HER2 dysregulation through overexpression of HER2 and
its ligand, loss of particular phosphatase, altered dimerization,
and decreased receptor turnover lead to an increase in signals and
cancer cell proliferation (1). The relevance of HER2 with ALDH1
and phospho-Akt has been shown (1).
On the other hand, inflammation may show a critical
role in the relapse of BC through the NFκB–IL-6 pathway,
which is involved in BCSC characterization and recurrence
of tumor progression. NFκB regulates interleukin-6 (IL-6) and
helps in the maintenance of BCSC and conversion of non-
CSC to CSC. In addition, some alterations in PI3K/mTOR
signaling has been detected in triple negative BC. PI3K/mTOR
inhibition through PI3K/mTOR inhibitor or TORC1 inhibitor
increases mammosphere formation, a CSC enrichment model,
and expression of CSCmarkers as well as fibroblast growth factor
1 (FGF1) and Notch1 expression in CSCs through increased
mitochondrial metabolism (73). Hence, this pathway could be
used as a target to make CSCs sensitive to inhibitors of TORC1,
which eradicates CSCs. BCSC phenotypes can be mediated by T-
box transcription factor 3 (Tbx3) through FGF/Tbx3 signaling
pathway. Tbx3 is a member of ancient proteins that is associated
with a variety of cancers such as gastric, pancreatic, liver, bladder,
and ovary as well as BC. Overexpression of T-box is critical for
the maintenance of CSC phenotypes such as self-renewal, drug
resistance, and metastasis (74).
It has been reported that steroid hormones are an important
player for induction and progression of BC. Despite involvement
of hormones and hormone receptors in BC, most studies have
reported that BCSCs are hormone receptor negative. It is
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FIGURE 2 | Activation of MAPK signaling pathway in BCSCs. Cooperation between EGFR and HER2 promotes EMT, tumor growth, motility, and ALDH activity
through activation of MNK and XIAP in a MAPK-dependent manner. In addition, chemotherapy promotes EMT and induces MAPK signaling pathway and expression
of Nanog/KIF4 in a HIF1-dependent manner.
suggested that ER+ to ER− transition is mediated by genetic and
epigenetic changes. Proliferation and expansion of ER− CSCs
could be driven by ER+ BC cells. The secretion of FGF in
ER+ BC is through ER signaling, by induction of EGF receptor,
Notch, and Wnt signaling through FGF paracrine manner in
ER− CSCs (75). In addition, progesterone induces proliferation
of BCSCs indirectly through NFκB signaling. NFκB signaling
activated in PR+ cells mediates binding of Receptor activator
of NFκB (RANK) with its ligand, RANKL, as a paracrine signal
transduction in PR-negative CSCs (75).
TGF-β Signaling Pathway
The other signaling pathway implicated in BCSCs is TGF-β
signaling pathway. TGF-β signaling in BCSCs may be mediated
through cytokine receptor signaling indirectly by stimulating
expression of family with sequence similarity 3-member C
(FAM3C)/interleukin-like EMT inducer (ILEI), an oncogenic
protein. Interaction of ILEI with LIFR, its receptor, promotes
cytokine receptor signaling through STAT3 activation to drive
EMT and metastasis (59). Besides, mTOR signaling, which
stabilizes stemness and drug resistance of BCSCs, is mediated
by TGF-β. Stable TGF-β exposure promotes proliferation and
drug resistance of BCSCs through increased mTOR signaling
(76). TGF-β signaling can be regulated by long non-coding
RNA (lncRNA), linc-ROR. Linc-ROR is a prognostic and
oncogenic factor that is critical in cancer stem cell maintenance.
Overexpression of linc-ROR upregulates TGF-β signaling, and
then, TGF-β signaling promotes proliferation and invasion of
BCSCs (77). Activated Smad and non-Smad through TGF-β
signaling pathway leads to the induction hyaluronan synthase 2
(Has2) and Has2 antisense (HAS2-AS) transcripts, high mobility
group AT-Hook 2 (Hmga2), and EMT inducing transcription
factors such as Snail, Snai1, Hmga2, and fibronectin 1 (78).
In addition, induction of Hmga2, Has2-AS, and Has2 are
accompanied by activation of Akt and Erk1/2 MAPK signaling.
These factors have been contributed to cancer stem cell
maintenance, migration, and EMT of BCSCs (78).
Wnt/β-Catenin and Notch Signaling
Pathway
Wnt and Notch signaling pathways are other signaling pathways
involved in cancer stem cell maintenance (60, 61). Wnt
and Notch signaling pathways may be activated by HIF-
2α overexpression, which is mediated by hypoxia. HIF-2α
overexpression promotes stem cell phenotype conversion, drug
resistance of BCSCs, and overexpression of BCSC markers (79).
Among several factors that have been involved in Wnt signaling,
overexpression of glycogen synthase kinase 3 beta (GSK3β)
correlates with poor patient survival. Overexpression of GSK3β
induces EMT and cancer stem cell properties in BCSCs (80). The
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contribution of Wnt signaling in stemness phenotypes of CSCs is
mediated by programmed death 1 (PD-1), which is overexpressed
in BCSCs. In addition, Wnt activators and Wnt inhibitors up-
and down-regulate PD-1, respectively. High expression of PD-
1 is associated with stem cell features (81). Recently, it has been
reported that kinesin family member 11 (KIF11), a motor protein
essential in mitosis, contributed to the regulation of Wnt/β-
catenin in BCSCs. It increases stemness phenotypes of BCSCs
through activation of Wnt/β-catenin (82). The other protein
that regulates Wnt/β-catenin in BCSCs is Nectin-4. Nectin-4,
a junction protein, is well-known as a BCSC marker and is
implicated in metastasis of BC and BCSCs. Overexpression of
Nectin-4 upregulates Wnt/β-catenin signaling pathway, which
is implicated in EMT, metastasis, and proliferation of BCSCs
(83). Wnt/β-catenin signaling regulates EMT by induction of
ZEB1 expression through binding β-catenin to ZEB1 promoter.
In addition, ZEB1 promoter has two STAT3 binding sites,
suggesting strong correlation between ZEB1 and STAT3 (68). In
addition, cytokeratin 5, which is enriched in BCSCs, alters the
function of β-catenin in two ways. Knockdown of cytokeratin
5 interrupts the transcription activity of β-catenin, even in
response to Wnt stimuli. On the other hand, cytokeratin 5
induced byWnt stimuli promotes deficiency of β-catenin and the
other junction protein of cell membrane such as E-cadherin. It
suggests dual function of cytokeratin 5 in relation to β-catenin in
the cell membrane of BCSCs (84).
It has been shown that there is an association between
estrogen signaling and Notch signaling in ERα+ BC cells,
which is mediated by Delta-like protein 1 (DLL1), Notch ligand.
Upregulation of Notch signaling by overexpression of DLL1
promotes proliferation, migration, angiogenesis, and cancer stem
cell phenotypes in ERα+ BC cells. This function for DLL1
is specific in ERα+ BC cells. Thus, it suggests that estrogen
and estrogen signaling stabilizes DLL1 through inhibition of
ubiquitylation and degradation of DLL1 (85).
In BCSCs, activated Notch signaling by jagged1 leads to
Akt phosphorylation and IκB kinase α (IKKα), NFκB, and
Notch1 activation. Recruitment of IKKα, NFκB, and Notch1
to antiapoptotic gene cIAP-2 promoter increases expression of
cIAP-2 (86) (Figure 3). Along with Notch1, activated Notch3
has contributed to the maintenance of BCSCs properties. It
is mediated by overexpression of cartilage oligomeric matrix
protein (COMP) in BCSCs. COMP increases interaction of
Notch3 and jagged1, which leads to overactivation of Notch3
signaling pathway (87).
Hedgehog Signaling Pathway
One of the signaling pathways upregulated in aggressive subtype
of breast cancer is the hedgehog signaling pathway (61). There
is an association between overexpression of hedgehog signaling
pathway regulators such as SHH, DHH, IHH, PTCH1, SMO,
and GLI1 with proliferation, migration, and aggressiveness of
BC (88). It has been observed that SHH/GLI1+ samples express
high levels of vimentin and Snail. It suggests that the hedgehog
signaling pathway and SHH/GLI1 axis are involved in EMT,
migration, and invasion of BCSCs (89).
Hippo Signaling Pathway
Among signaling pathways involved in CSCs, the Hippo pathway
plays an important role in organogenesis and regeneration.
Molecules that regulate Hippo signaling included regulatory
kinases such as MST1, MST2, LATS1, LATS2, SAV1, MOB kinase
1A,MOB kinase 1B, and transcriptional coactivators such as TAZ
and YAP. Alteration in Hippo signaling through deregulation
of these molecules leads to increased cell proliferation and
tissue overgrowth in mammary. Phosphorylated TAZ and YAP
mediated by activation of kinase cascade suppresses the inclusion
of TAZ and YAP into the nucleus as a result of the overexpression
of TAZ and YAP and deregulation of kinases. The inclusion of
TAZ and YAP into the nucleus leads to transcription of TAZ
and YAP target genes involved in cell proliferation, migration,
and invasion as well as resistance to chemotherapy (Figure 3).
Overexpression of TAZ/YAP has been reported in BCSCs to lead
to increased activity of MDR protein and cooperation between
TAZ and ECM (90).
Toll-Like Receptor Activity
Toll-like receptors (TLRs) are a class of proteins implicated
in inflammatory signaling and tumorigenesis (91). TLRs are
overexpressed in a variety of cancers such as esophageal,
gastric, as well as BC (91). Among TLRs, TLR2, and TLR3 are
overexpressed in BCSCs. TLR2 and its ligand, high-mobility-
group box 1 (HMGB1), display a key role in BCSC phenotypes
such as self-renewal and metastatic and tumorigenic activity
through inducing TGF-β and IL-6 secretion, Smad3 and STAT3
activation, and IκBα phosphorylation (92). In addition, activation
of TLR3 promotes BC cells to BCSC phenotypes. Activation
of TLR3 leads to coactivation of β-catenin and NFκB signaling
pathways essential for increased BCSC phenotypes (91).
CHEMOTHERAPY AND RADIOTHERAPY
RESISTANCE IN BCSCs
BCSCs are the main cause of chemotherapy and radiotherapy
resistance of BC. These cells may up- or down-regulated essential
genes and then initiate signaling pathways, which make tumors
more aggressive than before and resistant to therapy. Several
mechanisms and molecules have been proposed in therapeutic
resistance of BCSCs. There are two main mechanisms: pump
and non-pump resistance. Non-pump resistance is related to
stimulation of BCL2 protein, an antiapoptotic protein, whereas
pump resistance is related to overexpression of ABCG2. ABCG2
can flush out the chemotherapy drugs, which dilutes the
concentration of intracellular drug (93). It has been reported that
Survivin, an inhibitor of apoptosis, is overexpressed in BC cells
as well as BCSCs. Survivin overexpression is related to reduced
apoptosis and increased drug resistance. Downregulation of
Survivin with anticancer agents such as prodigiosin may
make BCSCs more sensitive to chemotherapeutic agents (94).
Furthermore, ALDH is contributed to BCSC therapy resistance
through direct and indirect manners. In direct manner, ALDH
removes oxygen radicals that are produced by chemo- and
radiotherapy, but in indirect situation, it produces nicotinamide
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FIGURE 3 | Notch signaling activity and Hippo pathway in BCSCs. As transcription factors, Notch1, phosphorylated Akt, and NFκB induce expression of CIAP2 and
inhibit apoptosis through Notch signaling activity in BCSCs. On the other hand, Hippo pathway promotes cell proliferation, migration, invasion, angiogenesis, and
chemotherapy resistance in BCSCs through translocation of YAP/YAZ into the nucleus and activation of Rac signaling. In addition, VEGFR/NRPs promotes stemness
phenotypes of BCSCs, indirectly through inhibition of Hippo pathway.
adenine dinucleotide phosphate (NADP), an antioxidant agent
(95). In addition, one of the specific mechanisms of BCSCs that
protects them against reactive oxygen species (ROS) production
by radiotherapy is using an ROS scavenging factor. ROS
scavenging is mediated by the upregulation of genes such as
catalase (CAT), superoxide dismutase (SOD), and glutathione
peroxidase (GPx) in BCSCs (95).
Various studies have reported other important molecules
involved in chemotherapy and radiotherapy resistance of BCSCs.
Caveolin-1 is involved in chemoresistance of BC, its expression
which is accompanied by coexpression of β-catenin and ABCG2.
Caveolin-1 is upregulated after BC chemotherapy in BCSCs.
Caveolin-1 promotes β-catenin/ABCG2 signaling via GSK3β
suppression and Akt activation (13). In addition, protein kinase
D1 (PRKD1) has been identified as a critical modulator of
stemness phenotypes and therapy resistance of BCSCs within
GSK3/β-catenin signaling. PRKD1 inhibitor and miR-34a, which
target PRKD1 through binding to the PRKD1 3′-untranslated
region (UTR), suppress tumor growth and proliferation as
well as drug resistance and induce apoptosis (96). Cells with
stem-like phenotypes such as having ALDH activity and drug
resistance exhibit high mitochondrial mass (97). It proposes that
chemo-resistance ability of BCSCs is driven by high function of
mitochondria (97).
Recent studies suggested that the level of cholesterol may
limit the efficiency of radiotherapy in cancer patients. There
is a relationship between plasma levels of lipoproteins and
radio-resistance in inflammatory BC and BCSCs. Transporters
of cholesterol (lipoproteins) such as high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and very-low-density
lipoprotein (VLDL) may regulate radiotherapy sensitivity.
Decreasing cellular cholesterol through treatment with
cholesterol-lowering agents such as HDL decreases radiotherapy
resistance, whereas VLDL decreases radiotherapy sensitivity (98).
EGFR and HER2, two growth factor receptors that have
been overexpressed in BCSCs, have an important role in
radiotherapy resistance of BCSCs. EGFR and HER2 inhibitors
such as GW572016 may make BCSCs sensitive to radiotherapy
as well as inhibit proliferation through inhibition of receptor
phosphorylation (99). The therapeutic resistance that is
modulated by EMT has been detected in various types of
cancer. Activation of genes related to EMT such as Snail and
Slug accompanied with activation of Notch signaling pathway
suppressed the expression of genes related to p53-mediated
apoptosis (100). One of the other prosurvival factor that is
involved in EMT and is induced through radiation in HER2+
BCSCs is NFκB (100). NFκB induces expression of HER2. HER2,
as a receptor, activates STAT3, which upregulates stemness
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markers. It suggests that there is a relationship between EMT,
cell stemness, and radioresistance of BCSCs (100). Non-CSCs
show more level of apoptosis during radiotherapy, whereas
CSCs confront with radiotherapy-induced damages through
activation of repair mechanisms (101). Activation of repair
mechanisms due to radiotherapy-induced damages is mediated
by zinc finger E-box binding homeobox 1 (ZEB1). ZEB1, as a
transcription factor, not only has been implicated in embryonic
development through EMT induction but also may promote
therapy resistance as well as metastasis and invasion in BCSCs.
The role of ZEB1 in radiotherapy resistance is modulated
by ATM and ATM and RAD3-related kinase (ATR) kinases.
Genetic deficiencies and DNA variations that are caused by
radiotherapy will be repaired through an ATM–ZEB1–CHK1
signaling axis activation. Activated ATM and ATR kinases
through radiotherapy-induced damages phosphorylate ZEB1.
ZEB1 interacts with deubiquitinase, ubiquitin-specific peptidase
7 (USP7) and promotes the deubiquitination ability of USP7 and
then stabilizes CHK1 (102) (Figure 4). Thus, targeting ZEB1
by inhibitors such as miR-205 and miR-200c as radiosensitizer
may be used as strategies for confronting with radio-resistance
of BCSCs (102). In addition, ZEB1 is contributed to non-CSC
conversion to CSCs in basal type of BC by inducing TGF-β, a
microenvironment stimuli of basal BC (102).
METASTASIS IN BCSCs
Metastasis has been described by two potential ability of BCSCs,
migration, and invasion. As mentioned above, not only EMT
is an important process in chemotherapy and radiotherapy
resistance but also it is implicated in metastasis of BCSCs. Snail, a
transcriptional repressor, is one of the most important inducer of
EMT through repression of E-cadherin expression. In addition,
the expression of snail maintains malignancy phenotypes of
BCSCs such as metastasis. Therefore, it could be suggested that
snail is a potential target to prevent metastasis of BCSCs (40).
Along with snail, ZEB1, an EMT inducer, promotes metastasis
and tumor progression in BCSCs through repression of E-
cadherin expression as well as epithelial polarity factors such as
HUGL2, Crumbs3, and Pals1-associated tight junction (PATJ)
expression. This leads to adhesion reduction and tumor cell
dissociation and finally increased invasion (102). Additionally,
deubiquitinating enzymes (DUBs), especially USP37 and USP2,
are involved in EMT, metastasis, as well as chemotherapy
resistance of BC and BCSCs. USP37 and USP2 are overexpressed
inmetastatic BC and BCSCs. USP37mediates hedgehog signaling
pathway through stabilizing components such as Smo and GLI-
1. Finally, hedgehog signaling drives to stemness, invasion,
and EMT of BCSCs (103). In addition, USP2 activates Bmi1
and EMT by stabilizing Twist through removing ubiquitylation
mediated by beta-transducin repeats-containing proteins (β-
TrCP), a cellular E3 ubiquitin ligase (104).
Extracellular matrix protein 1 (ECM1) is an important
prognosis marker for the invasion of breast cancer as well as
migration and drug resistance. In addition, ECM1 controls the
expression of genes involved in EMT and BCSC maintenance
through induction of Mucin1 (MUC1). The cytoplasmic tail
of MUC1 has a physical association with β-catenin that
stabilizes and increases posttranslational expression of β-catenin.
Therefore, altered expression of β-catenin changes the expression
of genes related to BCSC phenotypes such as invasion and EMT
progression (105).
CD36, a member of the scavenger receptor family with
binding to its receptor, thrombospondin-1 (TSP-1) plays an
important role in metastasis of BCSCs through several pathways.
CD36 binds to TSP-1 and TGF-β1 and promotes proliferation
and migration of BCSCs. On the other hand, it can interact with
NFκB and STAT3, which express genes related to carcinogenesis.
In addition, CD36 has a main role in BCSC metastasis
through uptaking fatty acids and regulating 3-hydroxy-3-
methylglutaryl-CoA synthase 2 (HMGCS2) enzyme and β-
oxidation of fatty acids (74). Furthermore, induction of NFκB
signaling pathway as a result of phosphodiesterase 3A (PDE3A)-
suppressed cAMP/PKA promotes expression of OCT4 as well as
translocation of CCDC88A, which boots invasion and metastasis
of BCSCs (106).
The role of CD44 in cancer progression, invasion, metastasis,
and angiogenesis of BCSCs is remarkable. There are several
ligands such as hyaluronic acid, osteopontin, and matrix
metalloprotease that bond to CD44. Binding ligands to CD44
induces cleavage of CD44 at extracellular and transmembrane
domain sites by membrane-type 1 matrix metalloprotease
(MT1-MMP) and presenilin-1/g secretase, respectively. Then,
the intracellular domain fragment of CD44 (CD44-ICD)
displaces into the nucleus and activates expression of genes
related to migration, invasion, metastasis, and angiogenesis of
BCSCs (107).
ANGIOGENESIS IN BCSCs
Cell survival mediated by hypoxic condition after radiotherapy
is contributed to the angiogenesis of CSCs (101). In both hypoxic
and normoxic conditions, CSCs show high expression of vascular
endothelial growth factor (VEGF). In addition, HIF-1, which is
stabilized in hypoxic condition, regulates expression of VEGF
(101). VEGF signaling has been contributed to proliferation,
drug resistance, and cancer stem cell phenotypes as well as
angiogenesis (108). Activated VEGF signaling reveals to be
responsible for activation of GTPase Rac1, which then inhibits
Hippo kinase LATS. The inhibition of Hippo kinase LATS leads
to the activation of Hippo effector TAZ and YAP. TAZ and
YAP, in a complex with transcription factor TEAD, repress
expression of Rac GTPase-activating protein (Rac GAP) and then
activate Rac signaling pathway, which promotes proliferation,
angiogenesis, and the other cancer stem cell phenotypes (108)
(Figure 3). In addition, VEGF-A/neuropilin-1 (NRP-1) axis is
contributed to stemness properties such as angiogenesis through
activating Wnt/β-catenin pathway.
The role of CD44 has been confirmed in angiogenesis as
well as metastasis. CD44 binds to its ligand, hyaluronic acid,
as well as VEGF through its binding domains and increases
angiogenesis (107).
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FIGURE 4 | Activation of repair mechanisms due to radiotherapy induced-damages in BCSCs. DNA damage induced by radiotherapy is repaired through an
ATM–ZEB1–CHK1 signaling axis. Activated ATM and ATR kinases phosphorylate ZEB1. ZEB1 interacts with USP7, a deubiquitylating enzyme, and promotes the
deubiquitylation ability of USP7 that stabilizes CHK1.
miRNAs UPREGULATED IN BCSCs
miRNAs are introduced as one of the non-coding RNAs
classes that suppress gene expression through inhibition of
translation. Several studies suggest that several miRNAs regulate
stemness phenotypes of BCSCs through targeting genes involved
in signaling pathways. Table 1 presents miRNAs that are
upregulated in BCSCs and are involved in BCSC maintenance
and phenotypes.
BCSCs AND THERAPY STRATEGIES
Substantial shreds of evidence support that resistance of
BCSCs to chemotherapy and radiotherapy have been associated
with metastasis and relapse of BC after treatment (109).
Therefore, discovering potential strategies and targeting
BCSCs could be effective to overcome the relapse of BC.
Recently, various strategies such as herbal medicine, biological
agents, anti-inflammatory drugs and monoclonal antibodies,
nanoparticles, and microRNAs have been studied for targeting
BCSCs. Signaling pathways that are dysregulated in BCSCs
are the best candidate for developing novel strategies
for targeting BCSCs. In addition to signaling pathway
inhibitors such as Notch and γ-secretase inhibitor (MK-0752),
hedgehog inhibitor (Vismodegib, GDC-0449), Wnt signaling
pathway inhibitor (PKF118-310 and pyrvinium pamoate),
PI3K/Akt/mTOR pathway inhibitor (Everolimus, RAD001),
CXCR2 inhibitor (Reparixin), and EGFR/HER2 inhibitors
(Lapatinib and Herceptin), which target signaling pathways
directly (110), offer several breast cancer treatment strategies via
targeting BCSCs.
Herbal Medicine
Recently, several studies have implicated natural components
and herbal medicine in BC treatment by targeting BCSCs
(111–113). These components have several advantages such
as fewer side effects in comparison with non-natural drugs.
Recently, it has been shown that Viola odorata extract, a herbal
medicine, decreases stemness potency and cell viability of BC-
cell-derived mammospheres as well as induction of apoptosis
(114). It has been reported that a natural component of
brown algae, phloroglucinol (PG), suppresses BCSC proliferation
through reduction of Oct4, Sox2, β-catenin, and CD44
expression. In addition, it inhibits KRAS, RAF1/ERK, and
PI3K/Akt signaling pathways in BCSCs (109). Capsaicin, an
active ingredient of chili peppers, has shown anticancer and
antiproliferation activity on BCSCs through inhibition of
translocation Notch intracellular membrane domain (NICD)
into the nucleus and inhibition of Notch signaling (115). In
addition, Psoralidin (Pso), a small herbal molecule effectively
inhibits Notch1 signaling, which leads to reduction in growth,
migration, and invasion of BCSCs through downregulation
of vimentin and β-catenin and upregulation of E-cadherin
expression (116).
Nobiletin, a flavonoid derived from citrus peel, has
anticancerous activity by binding to CD36 and suppressing
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CD36/STAT3/κ-κB signaling axis, which inhibits angiogenesis,
migration, and metastasis of BCSCs (74). Apigenin, the other
flavonoid detected in many herbal medicine, suppresses stemness
properties of BC cells by inhibiting YAP/TAZ activity through
disrupting YAP/TAZ-TEADs complex (79).
5,6,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one
(Baicalein), an active component of Scutellaria baicalensis
Georgi, targets BCSCs and suppresses stemness potential of
BCSCs by induction of apoptosis through inducing ROS
and changing mitochondrial membrane potentials as well as
downregulating Wnt/β-catenin pathway (117).
Biological Agents
Implicating biological agents against BCSCs have been observed
in several researches. FK506-binding protein-like (FKBPL)
and AD-01 (one of the its derivatives) are novel biological
agents that have an effective role in inhibiting tumor growth
initiation, angiogenesis, and metastasis of BC cells as well as
BCSCs through targeting CD44 pathway and downregulating
DLL4, a Notch ligand, and Notch4 (118, 119). Disabling
mitochondria in BCSCs could be introduced as an effective way
of eradicating BCSCs. Mitocans are a group of components
that target mitochondria and induce apoptosis in BCSCs.
They could be suggested as anticancer agents. Mito Vitamin
E succinate (MitoVES) is a component of mitocans that
induces apoptosis in BCSCs through targeting mitochondria
complex II (120). Targeting PI3K/Akt signaling pathway, as an
important pathway in MDR of BCSCs, has been suggested as
an antineoplastic strategy to overcome the MDR phenotype
of BCSCs. PI3K inhibitors such as BKM120 inhibit PI3K/Akt
signaling, which leads to activation of apoptotic caspases such
as caspase-3/7 and caspase-9 (58). In addition, a novel chemical
component, 1-ferrocenyl-3-(4-methylsulfonylphenyl)propen-1-
one (FMSP), targets several signaling pathways such as
Wnt/β-catenin and Notch through downregulating Wnt1,
Notch1, β-catenin, SOX2, CXCR4, and ALDH1A1 as well
as apoptosis induction through ROS production (121). In
addition, 5-aza-2′-deoxycytidine (DAC), an epigenetic drug,
induces differentiation, S phase cell cycle arrest through
induced expression of p53, p21, p16, p15, BRCA1, and BRCA2,
and reduced expression of ABCG2 through demethylation
mechanism (122).
Anti-inflammatory Agents and Monoclonal
Antibodies
Developing anti-inflammatory drugs and monoclonal antibodies
could be useful for preventing proliferation, metastasis, and
drug resistance of BCSCs. Aspirin (ASA) prodrug is one of
the anti-inflammatory drugs that has shown antineoplastic
activity without toxicity through targeting NFκB–IL6 pathway
and cyclooxygenase (COX)/prostaglandin in BCSCs (123, 124).
In addition, ASA blocks angiogenic factors that are secreted
by CSCs and contributed to tumor angiogenesis. It blocks
paracrine–autocrine signaling between endothelial cells and
CSCs (125).
Previously, it has been shown that EGFR is a critical player
in tumor initiation, metastasis, and drug resistance of BC and
BCSCs. Therefore, implication of EGFR monoclonal antibody
such as Cetuximab effectively could be suggested as a useful
strategy to reduce BCSC population (126). Bevacizumab, an
anti-VEGF antibody targets VEGF and suppresses angiogenesis
of BCSCs (127). Recently, BCSC markers such as CD44
and EpCAM have been used for developing therapeutically
monoclonal antibodies. For example, MT110, anti-EpCAM and
P245, and anti-CD44 are potential therapeutic monoclonal
antibodies that have exhibited anticancer activity against
BCSCs (128).
Nanoparticles
Recently, nanoparticles have been an interesting approach
for targeting cancer cells especially CSCs. Specific phenotypes
of CSCs can be used for designing nanoparticles. Among
nanomaterials, mesoporous silica particles have demonstrated
efficient drug delivery in cancer therapy. It has been designed
based on glycolytic phenotype and Notch activity of CSCs.
Uptaking mesoporous silica nanoparticles accompanied with γ-
secretase inhibitor by BCSCs targets Notch signaling pathway
and eliminates stemness properties of BCSCs.
MicroRNAs
miRNAs are the most attractive topics in BCSCs. They have
been implicated in targeting BCSCs through several signaling
pathways. Table 2 presents tumor-suppressing miRNAs that are
downregulated in BCSCs and are implicated for targeting BCSCs
as a novel strategy with their suggested functional pathways.
CONCLUSION
BCSCs are one of the main reasons for tumor development
and recurrence of BC after treatment. These cells have some
specific markers: CD44+/CD24−, ALDH activity, and ESA or
CD326 (EpCAM), CD133, CD166, Lgr5, CD47, and ABCG2
in different types of BCs. BC cells’ conversion to BCSCs
due to genetic and epigenetic changes leads to deregulation
of several signal transduction pathways such as MAP kinase,
PI3K/Akt/NFκB, TGF-β, Wnt/β-catenin, Notch, hedgehog, and
Hippo signaling. Deregulation of these signaling pathways
and other factors leads to several stemness phenotypes such
as chemotherapy and radiotherapy resistance, EMT, invasion,
migration, and angiogenesis. Additionally, the role of miRNAs
in stemness features of BCSCs is remarkable. A variety of
miRNAs upregulated in BCSCs are contributed to stemness
phenotypes of BCSCs. Recently, implicating novel treatment
strategies such as herbal medicine, biological agents, anti-
inflammatory drugs, monoclonal antibodies, nanoparticles, and
microRNAs that target different signaling pathways and other
deregulated genes directly or indirectly could be effective for
targeting BCSCs.
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